Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G/A for VERA THERAPEUTICS INC COMMON STOCK (VERA).
- Disclosed ownership: 7.7%.
- Date of event: 31 Dec 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 31 Dec 2025 SCHEDULE 13G/A Report for VERA THERAPEUTICS INC COMMON STOCK (VERA)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Security
- VERA THERAPEUTICS INC COMMON STOCK
- Symbol
- VERA
- Shares outstanding
- 70,934,909 shares
- Disclosed Ownership
- 5,461,988 shares
- Ownership
- 7.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 10:26:21 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 7.7% ownership in VERA THERAPEUTICS INC COMMON STOCK (VERA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 10:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 7.7% | 5,461,988 | 5,376,319 | 0 | Ellen York | Vice President |